Aducanumab can slow the progress of Alzheimer
Aducanumab, an antibody show
benefits in patient who are administered with it in very earliest stage of Alzheimer.
In a very small volunteer set of 166 patients, a trial for testing Aducanumab
efficiency in combating dementia was tested. The trial results were presented
at the International Conference on Alzheimer’s and Parkinson’s Diseases andRelated Neurological Disorders in Nice, France.
At one end, a small sample set is
not very encouraging sign but the fact that there are no reliable alternative
as drugs to halt or even slow the progress of dementia – of which Alzheimer’s
is the most common type – means that any positive results will be greeted with
enthusiasm.
The higher the dose of drug the
patient was given, the greater the reduction. Tests also showed that those
people who took the drug had a slower rate of mental decline than those who did
not – although the trial was not set up primarily to see whether there was any
effect on cognition.
Biogen Idec, the company that
made the drug, announced it would be moving quickly into large-scale trials
which will involve hundreds, if not thousands, of people.
